Blood Cancer Journal (Jan 2022)
Efficacy of CDK9 inhibition in therapy of post-myeloproliferative neoplasm (MPN) secondary (s) AML cells
- Warren Fiskus,
- Taghi Manshouri,
- Christine Birdwell,
- Christopher P. Mill,
- Lucia Masarova,
- Prithviraj Bose,
- Tapan M. Kadia,
- Naval Daver,
- Courtney D. DiNardo,
- Gautam Borthakur,
- Joseph D. Khoury,
- Srdan Verstovsek,
- Kapil N. Bhalla
Affiliations
- Warren Fiskus
- The University of Texas M.D. Anderson Cancer Center
- Taghi Manshouri
- The University of Texas M.D. Anderson Cancer Center
- Christine Birdwell
- The University of Texas M.D. Anderson Cancer Center
- Christopher P. Mill
- The University of Texas M.D. Anderson Cancer Center
- Lucia Masarova
- The University of Texas M.D. Anderson Cancer Center
- Prithviraj Bose
- The University of Texas M.D. Anderson Cancer Center
- Tapan M. Kadia
- The University of Texas M.D. Anderson Cancer Center
- Naval Daver
- The University of Texas M.D. Anderson Cancer Center
- Courtney D. DiNardo
- The University of Texas M.D. Anderson Cancer Center
- Gautam Borthakur
- The University of Texas M.D. Anderson Cancer Center
- Joseph D. Khoury
- The University of Texas M.D. Anderson Cancer Center
- Srdan Verstovsek
- The University of Texas M.D. Anderson Cancer Center
- Kapil N. Bhalla
- The University of Texas M.D. Anderson Cancer Center
- DOI
- https://doi.org/10.1038/s41408-022-00618-4
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 5
Abstract
No abstracts available.
